文献速递心力衰竭与心肌病

人诱导多能干细胞心脏球体直接注射再生非人灵长类心脏

Regeneration of Nonhuman Primate Hearts With Human Induced Pluripotent Stem Cell-Derived Cardiac Spheroids.
PubMed 文献 · Circulation · 2024-04-26

该研究在食蟹猴心肌梗死模型中直接注射人诱导多能干细胞来源的心脏球体(hiPSC-CSs),分别使用含2×10^7与6×10^7心肌细胞的产品,评估移植效果与心律失常风险。结果显示增加细胞剂量可显著提高植入率并带来长期收缩功能获益,心律失常风险可接受。

要点

  • 直接注射hiPSC-CSs可在灵长类梗死心脏中实现植入并改善收缩功能
  • 2×10^7心肌细胞剂量收缩功能获益短暂且植入有限
  • 6×10^7心肌细胞剂量植入更显著、收缩功能获益持久但心律失常略增

核心结论

  • 直接注射hiPSC-CSs可恢复受损灵长类心脏的收缩功能,且移植后心律失常风险可接受。
  • 功能获益机制尚未完全阐明,但结果为使用等效心肌细胞产品开展临床试验提供了有力依据。

研究设计与样本

  • 两项独立实验,使用食蟹猴在移植前2周建立心肌梗死模型。
  • 第一项实验10只食蟹猴随机接受含2×10^7心肌细胞的hiPSC-CSs或载体,移植后12周处死行组织学分析。
  • 第二项实验重复等效移植研究,使用更多心肌细胞(6×10^7)。
  • 观察期间监测心脏功能与心律失常。

主要发现

  • 接受含2×10^7心肌细胞hiPSC-CSs的受体植入有限,移植后4周缩短分数较载体组一过性升高(26.2±2.1% 对 19.3±1.8%,P<0.05),移植后心律失常发生率低。
  • 增加心肌细胞剂量后植入显著增加并带来长期收缩功能获益:移植后12周缩短分数22.5±1.0% 对 16.6±1.1%(P<0.01),左心室射血分数49.0±1.4% 对 36.3±2.9%(P<0.01)。
  • 接受含6×10^7心肌细胞hiPSC-CSs的受体移植后心律失常发生率略有增加。

关键数值与推荐

  • 第一项实验:hiPSC-CSs含2×10^7心肌细胞,移植后4周缩短分数26.2±2.1% 对 19.3±1.8%,P<0.05。
  • 第二项实验:hiPSC-CSs含6×10^7心肌细胞,移植后12周缩短分数22.5±1.0% 对 16.6±1.1%,P<0.01。
  • 第二项实验:移植后12周左心室射血分数49.0±1.4% 对 36.3±2.9%,P<0.01。

临床怎么用

  • 提示hiPSC-CSs直接心肌内注射可作为心脏修复的候选策略,需权衡细胞剂量与移植后心律失常风险。
  • 临床转化前需在等效产品中进一步明确最佳细胞剂量与心律失常监测方案。

局限性

  • 功能获益机制未完全阐明。
  • 研究为非人灵长类动物实验,样本量有限(第一项实验10只食蟹猴),尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical application of human induced pluripotent stem cell-derived cardiomyocytes (CMs) for cardiac repair commenced with the epicardial delivery of engineered cardiac tissue; however, the feasibility of the direct delivery of human induced pluripotent stem cell-derived CMs into the cardiac muscle layer, which has reportedly induced electrical integration, is unclear because of concerns about poor engraftment of CMs and posttransplant arrhythmias. Thus, in this study, we prepared purified human induced pluripotent stem cell-derived cardiac spheroids (hiPSC-CSs) and investigated whether their direct injection could regenerate infarcted nonhuman primate hearts. METHODS: We performed 2 separate experiments to explore the appropriate number of human induced pluripotent stem cell-derived CMs. In the first experiment, 10 cynomolgus monkeys were subjected to myocardial infarction 2 weeks before transplantation and were designated as recipients of hiPSC-CSs containing 2×107 CMs or the vehicle. The animals were euthanized 12 weeks after transplantation for histological analysis, and cardiac function and arrhythmia were monitored during the observational period. In the second study, we repeated the equivalent transplantation study using more CMs (6×107 CMs). RESULTS: Recipients of hiPSC-CSs containing 2×107 CMs showed limited CM grafts and transient increases in fractional shortening compared with those of the vehicle (fractional shortening at 4 weeks after transplantation [mean ± SD]: 26.2±2.1%; 19.3±1.8%; P<0.05), with a low incidence of posttransplant arrhythmia. Transplantation of increased dose of CMs resulted in significantly greater engraftment and long-term contractile benefits (fractional shortening at 12 weeks after transplantation: 22.5±1.0%; 16.6±1.1%; P<0.01, left ventricular ejection fraction at 12 weeks after transplantation: 49.0±1.4%; 36.3±2.9%; P<0.01). The incidence of posttransplant arrhythmia slightly increased in recipients of hiPSC-CSs containing 6×107 CMs. CONCLUSIONS: We demonstrated that direct injection of hiPSC-CSs restores the contractile functions of injured primate hearts with an acceptable risk of posttransplant arrhythmia. Although the mechanism for the functional benefits is not fully elucidated, these findings provide a strong rationale for conducting clinical trials using the equivalent CM products.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kobayashi H, Tohyama S, Ichimura H, et al. Regeneration of Nonhuman Primate Hearts With Human Induced Pluripotent Stem Cell-Derived Cardiac Spheroids. Circulation. 2024. PMID: 38666382. doi:10.1161/CIRCULATIONAHA.123.064876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。